close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by INVENTIVA

< Previous 1 2 3 Next >
News headline image
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva reports its 2024 full year results and provides a business update
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
From INVENTIVA
Via GlobeNewswire
News headline image
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
From INVENTIVA
Via GlobeNewswire
News headline image
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
From INVENTIVA
Via GlobeNewswire
News headline image
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva reports 2024 Third Quarter Financial Information¹
From INVENTIVA
Via GlobeNewswire
News headline image
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva announces a €20.1 million issuance of royalty certificates
From INVENTIVA
Via GlobeNewswire
News headline image
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
From INVENTIVA
Via GlobeNewswire
News headline image
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
From INVENTIVA
Via GlobeNewswire
News headline image
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
From INVENTIVA
Via GlobeNewswire
News headline image
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
From INVENTIVA
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today